SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

15 May 2024 Evaluate
The revenue for the March 2024 quarter is pegged at Rs. 4413.75 millions, about 13.52% up against Rs. 3888.14 millions recorded during the year-ago period.The company reported a drastic decline of -88.81% in the quarter ended March 2024 to Rs. 6.00  millions from Rs. 53.63 millions  .Operating profit surged to 499.80 millions from the corresponding previous quarter of 376.96 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 4413.75 3888.14 13.52 16856.32 15246.09 10.56 16856.32 15246.09 10.56
Other Income 14.68 179.25 -91.81 130.30 422.39 -69.15 130.30 422.39 -69.15
PBIDT 499.80 376.96 32.59 1661.35 979.02 69.70 1661.35 979.02 69.70
Interest 241.60 196.58 22.90 871.42 794.76 9.65 871.42 794.76 9.65
PBDT 258.20 180.38 43.14 789.93 184.26 328.70 789.93 184.26 328.70
Depreciation 147.00 148.49 -1.00 607.18 591.19 2.70 607.18 591.19 2.70
PBT 111.20 31.89 248.70 182.75 -406.93 -144.91 182.75 -406.93 -144.91
TAX 105.20 -21.74 -583.90 132.74 -182.37 -172.79 132.74 -182.37 -172.79
Deferred Tax 105.20 -21.74 -583.90 132.74 -182.37 -172.79 132.74 -182.37 -172.79
PAT 6.00 53.63 -88.81 50.01 -224.56 -122.27 50.01 -224.56 -122.27
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) 9.74 8.43 15.47 8.62 5.60 53.86 8.62 5.60 53.86

Nectar Lifesciences Share Price

11.94 0.12 (1.02%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×